HHHuaizhen He

Huaizhen He

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Huaizhen He has a total of 124 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Noninternalizing Fluorescent Probe Targeting Mas-Related G Protein Coupled Receptor X2: A Tool for Antagonist Screening and Receptor Detection in Blood Samples

    by Jiayu Lu, Yi Shan, Na Li, Xiaoxue Mo, Yajing Hou, Delu Che, Fanli Yang, Langchong He, Cheng Wang, Huaizhen He

    MrgX2 has emerged as a critical target in allergic diseases, and the development of targeted fluorescent probes would significantly advance the study and treatment of these conditions. However, receptor internalization limits current MrgX2 probes, which are mostly agonist-based, compromising their labeling accuracy and stability. Here, we introduce TM2, a noninternalizing fluorescent probe with high specificity and favorable fluorescent properties for MrgX2. TM2 enables stable, precise receptor labeling in live cells without the induction of cellular internalization or activation. This capability facilitated the development of a competitive binding assay that screened 140 compounds, identifying C104 as a potent MrgX2 antagonist with validated antiallergic efficacy in vitro and in vivo. Moreover, TM2 quantitatively differentiated MrgX2 expression in clinical blood samples from atopic dermatitis patients versus controls, highlighting its diagnostic potential. Collectively, this work presents TM2 as a versatile tool for advancing the diagnosis and treatment of MrgX2-mediated allergic diseases.

  • Correction to Optimization of MrgX2 Antagonists Based on the “Cell Membrane Chromatography-Molecular Docking” Approach

    by Jiayu Lu, Xin Jia, Yi Shan, Zhaomin Xia, Hua Qian, Siqi Wang, Wen Yang, Wenyu Yang, Delu Che, Xinlei Zhang, et al.

  • Optimization of MrgX2 Antagonists Based on the “Cell Membrane Chromatography-Molecular Docking” Approach

    by Jiayu Lu, Xin Jia, Yi Shan, Zhaomin Xia, Hua Qian, Siqi Wang, Wen Yang, Wenyu Yang, Delu Che, Xinlei Zhang, et al.

    Molecular docking is emerging as a pivotal tool in drug discovery. To improve efficiency, the ligand-receptor affinity predicted by molecular docking needs to be revised by using actual affinity data. Cell membrane chromatography (CMC), a biomimetic chromatographic technique, is frequently employed in the affinity evaluation of the ligand-membrane receptor. In this study, we developed an optimization approach by integrating CMC with molecular docking, specifically designed for the optimization of MrgX2 antagonists. In this study, we developed a "KD-r_psp_MMGBSA_dG_Bind_Lipo" approach by integrating CMC with molecular docking for the optimization of MrgX2 antagonists. Utilizing this approach, compound BER-5 was designed, synthesized, and demonstrated as a potent MrgX2 antagonist with antiallergic effects in vitro and in vivo. The successful application of this approach demonstrates its potential and rationality for further optimizing MrgX2 antagonists and holds promise for broader application in drug development targeting GPCRs on the membrane.


  • Screening and discovery of volatile allergenic components from artemisia ordosica in Yulin region of Northern China

    by Xiaoxue Mo, Cheng Wang, Yi Shan, Siqi Wang, Wen Yang, Zhaomin Xia, Zhanguo Qiao, Tao Zhang, Yuanyuan Ding, Rui Liu, et al.


  • Design and synthesis of a new environmentally sensitive small-molecule fluorescent probe for MRGPRX2

    by Xiaoxue Mo, Yuexin Lv, Jiayu Lu, Yajing Hou, Hua Qian, Cheng Wang, Huaizhen He


  • MrgX2-Targeting Ligand Screen for Antipseudoallergic Agents by Immobilized His-Tag-Fused Protein Technology

    by Zhaomin Xia, Qiumei Zhu, Yi Shan, Jiayu Lu, Meidi An, Xiaoxue Mo, Siqi Wang, Wen Yang, Hua Qian, Huaizhen He, et al.

    Mas-related G protein-coupled receptor X2 (MrgX2) plays a key role in pseudoallergy reactions; thus, it is of great significance to screen compounds with antipseudoallergy activity via MrgX2. Cell membrane chromatography (CMC) demonstrates great potential in drug screening, but it requires further optimization to improve its specificity and stability. In this study, a new CMC system incorporating His-tag-oriented immobilized proteins was constructed to screen MrgX2 antagonists. Single His-tag-fused MrgX2 was extracted intactly and covalently bond to divinyl sulfone-modified amino silica gel to obtain bioaffinity composites. The characterized composites were utilized to establish a MrgX2-His-tag@VS/CMC system to screen MrgX2 antagonists. Compound Z-3578 was screened from a G protein-coupled receptor compound library of 3010 compounds and revealed its efficient antipseudoallergy activity in vitro and in vivo via MrgX2. In conclusion, the new oriented-immobilized CMC system will provide an efficient analytical tool for screening active precursors.


  • Twin Strep-Tag Modified CPT1A Mitochondrial Membrane Chromatography in Screening Lipid Metabolism Regulators

    by Wu Su, Peng Yang, Fanding Xu, Tingrong Zhang, Lizhuo Wang, Hua Li, Li Cui, Zhiwei Yang, Huaizhen He, Shengli Han, et al.

    Mitochondrial Membrane Chromatography (MMC) is a bioaffinity chromatography technique developed to study the interaction between target proteins embedded in the mitochondrial membrane and their ligand compounds. However, the MMC stationary phases (MMSP) prepared by chemical immobilization are prone to nonspecific binding in candidate agent screening inevitably. To address these challenges, Twin Strep-Tag/Strep Tactin was employed to establish a specific affinity system in the present study. We prepared a carnitine palmitoyltransferase 1A (CPT1A) MMSP by specifically linking Strep-tactin-modified silica gel with the Twin Strep-Tag on the CPT1A-oriented mitochondrial membrane. This Twin Strep-Tag/Strep Tactin modified CPT1A/MMC method exhibited remarkably better retention behavior, longer stationary phase lifespan, and higher screening specificity compared with previous MMC systems with glutaraldehyde immobilization. We adopted the CPT1A-specific MMC system in screening CPT1A ligands from traditional Chinese medicines, and successfully identified novel candidate ligands: ononin, isoliquiritigenin, and aloe-emodin, from Glycyrrhiza uralensis Fisch and Senna tora (L.) Roxb extracts. Biological assessments illustrated that the compounds screened promote CPT1A enzyme activity without affecting CPT1A protein expression, as well as effectively reduce the lipid droplets and triglyceride levels in the high fat induction HepG2 cells. The results suggest that we have developed an MMC system, which is promising for studying the bioaffinity of mitochondrial membrane proteins to candidate compounds. This system provides a platform for a key step in mitochondrial medicine discovery, especially for bioactive molecule screening from complex herbal extracts.


  • Synthesis and anti‐SARS‐CoV‐2 activity of amino acid modified cephalotaxine derivatives

    by Min Si, Meidi An, Zhaomin Xia, Xiaoxue Mo, Jiayu Lu, Huaizhen He, Cheng Wang

    The severe acute respiratory syndrome coronavirus (SARS‐CoV‐2) pandemic has triggered a significant impact on global public health security, it is urgent to develop effective antiviral drugs. Previous studies have found that binding to ACE2 is a key step in the invasion of SARS‐CoV‐2 into host cells, so virus invasion can be inhibited by blocking ACE2, but there are few reports on this kind of specific inhibitor. Our previous study found that Harringtonine (HT) can inhibit the entry of SARS‐CoV‐2 spike pseudovirus into ACE2h cells, but its relatively high cytotoxicity limits its further development. Amino acid modification of the active components can increase their solubility and reduce their cytotoxicity. Therefore, in this study, seven new derivatives were synthesized by amino acid modification of its core structure Cephalotaxine. The target compounds were evaluated by cell viability assay and the SARS‐CoV‐2 spike pseudovirus entry assay. Compound CET‐1 significantly inhibited the entry of pseudovirus into ACE2h cells and showed less cytotoxicity than HT. Molecular docking results showed that CET‐1 could bind TYR83, an important residue of ACE2, just like HT. In conclusion, our study provided a novel compound with more potential activity and lower toxicity than HT on inhibiting the SARS‐CoV‐2 spike pseudovirus infection, which makes it possible to be a lead compound as an antiviral drug in the future.


  • Exogenous analogues of substance P trigger pseudo-allergic reactions through activation of MRGPRX2

    by Yi Shan, Jiayu Lu, Na Li, Xiaoxue Mo, Cheng Wang, Huaizhen He

    Pseudo-allergic reactions are non-IgE-mediated immediate allergic reactions, and MRGPRX2 is a potential important target for pseudo-allergic reactions. Currently, numerous reports focus on the induction of pseudo-allergic reactions by small molecule drugs and endogenous peptides. However, insufficient attention has been paid to the pseudo-allergic reactions induced by exogenous peptides through MRGPRX2. Therefore, this study selected immunogenic peptide composition HL-9-5, which has a structure and properties similar to substance P, and its analogue HL-9-4. We conducted experiments through LAD2 cell β-hexosaminidase release, histamine release, cytokine release and MRGPRX2-HEK293 cell calcium mobilization assay in vitro, and mice paw swelling, serum histamine detection, hindpaw skin H&E and TB staining in vivo demonstrated that HL-9-4 and HL-9-5 can trigger pseudo-allergic reactions via MRGPRX2. Molecular docking further showed that SP, HL-9-4 and HL-9-5 can act on the same cavity in MRGPRX2, and ASP-174 was identified as the conserved site of interaction for all three compounds. Therefore, HL-9-4 and HL-9-5 are exogenous analogues of substance P that can induce pseudo-allergic reactions. This study laid the foundation for research on the mechanism of pseudo-allergic reactions induced by exogenous peptide compounds and was also of great significance for subsequent research on the interaction between various ligands and MRGPRX2 and for the development of peptide antagonists.